Zhang F, et al. - This multicentric investigation was pursued to determine the efficacy of intravenous belimumab plus standard of care (SoC) as a treatment option for patients with systemic lupus erythematosus (SLE). Findings demonstrated that SLE treatment with belimumab in patients from North East Asia significantly improved disease activity in these subjects, while reducing prednisone use, with no new safety issues.